CLOs on the Move

Longeveron

www.longeveron.com

 
Longeveron is a clinical stage biotechnology company that develops cellular therapies for aging-related and life-threatening conditions. Their lead investigational product is Lomecel B™, which is derived from culture-expanded medicinal signaling cells ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Lupin

Lupin is a USD 2.55 billion innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Particle Dynamics

Particle Dynamics is a company that provides innovative technologies, quality ingredients, and custom processing capabilities that deliver solutions for the pharmaceutical, consumer health, OTC, and nutraceutical markets.

Worldwide Clinical Research

Worldwide Clinical Research is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elite Pharmaceuticals

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite`s strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite`s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product.

Stone and Magnanini

Stone & Magnanini is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.